Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra in Moderately to Severely Active Crohn's Disease
NCT07196722Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Peptides, Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of icotrokinra in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Oct 2025; status: recruiting.
02
Drugs
icotrokinra
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07196722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196722.